Tryptamine Therapeutics (ASX:TYP) appointed Herwig Janssen as non-executive chairman, effective Monday, succeeding Mark Davies, according to a same-day Australian bourse filing.
Janssen most recently served as vice president for licensing and acquisitions of emerging markets at J&J Innovative Medicine, a unit of Johnson & Johnson, for nearly three decades.
The company's shares rose 6% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.